{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:04:24Z","timestamp":1791464664984,"version":"4.3.4"},"reference-count":46,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-based GVHD prophylaxis. Methods: Patients received grafts from HLA-matched donors (47.4%), mismatched unrelated donors (MMUD, 33.2%), or haploidentical donors (19.4%). Results: The estimated 2-year non-relapse mortality (NRM) was 11.8%, 26.4%, and 22.4%, respectively (p = 0.0528). The cumulative incidence (Cum.Inc) of acute and chronic GVHD, immunosuppression duration, and post-transplant outcomes were similar across donor types. The day +30 Cum.Inc of bacterial bloodstream infections (BSI) tended to be higher in HLA-matched transplants (49.2%, p = 0.073), while HHV-6 reactivation showed a trend toward higher frequency in haploidentical transplants (22.4%, p = 0.068). Cytomegalovirus (CMV) reactivation occurred between days +30 and +100, with the highest Cum.Inc in MMUD (59.5%, p = 0.033). BK virus-associated hemorrhagic cystitis showed a trend toward higher incidence in MMUD (22.3%, p = 0.056). Respiratory and fungal infections were most frequent in the first 100 days, with comparable rates across donor types. By day +180, most patients achieved immune reconstitution, with normalization of CD4+ T cells, CD8+ T cells, and IgG levels, independent of donor type. Conclusions: Patients undergoing allo-HCT with PTCY-based prophylaxis experience a high infectious density rate early post-transplant, which decreases after 6 months as immune reconstitution progresses, regardless of donor type.<\/jats:p>","DOI":"10.3390\/cancers17071109","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T06:58:43Z","timestamp":1742972323000},"page":"1109","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on Infectious Complications and Immune Reconstitution According to Donor Type"],"prefix":"10.3390","volume":"17","author":[{"given":"Beatriz","family":"Merch\u00e1n-Mu\u00f1oz","sequence":"first","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Su\u00e1rez-Lled\u00f3","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-0921","authenticated-orcid":false,"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-6318","authenticated-orcid":false,"given":"Tommaso Francesco","family":"Aiello","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-4073","authenticated-orcid":false,"given":"Antonio","family":"Gallardo-Pizarro","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4777-9643","authenticated-orcid":false,"given":"Paola","family":"Charry","sequence":"additional","affiliation":[{"name":"Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-4508","authenticated-orcid":false,"given":"Joan","family":"Cid","sequence":"additional","affiliation":[{"name":"Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-833X","authenticated-orcid":false,"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[{"name":"Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Pedraza","sequence":"additional","affiliation":[{"name":"Apheresis and Cellular Therapy Unit, Hemotherapy and Hemostasis Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Mart\u00ednez-Roca","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ares","family":"Guardia","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8475-0643","authenticated-orcid":false,"given":"Laia","family":"Guardia","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Carreras","sequence":"additional","affiliation":[{"name":"Josep Carreras Institute Against Leukemia, Campus Clinic, 08916 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garc\u00eda-Vidal","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3733-590X","authenticated-orcid":false,"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-7306","authenticated-orcid":false,"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-3682","authenticated-orcid":false,"given":"Mar\u00eda Queralt","family":"Salas","sequence":"additional","affiliation":[{"name":"Hematopoietic Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases (ICAMS), Hospital Cl\u00ednic Barcelona, 08036 Barcelona, Spain"},{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Faculty of Medicine and Health Sciences, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12185-022-03428-3","article-title":"Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide","volume":"116","author":"Nakamae","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/bmt.2014.108","article-title":"Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes","volume":"49","author":"Bhamidipati","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41409-021-01328-4","article-title":"Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide","volume":"56","author":"Esquirol","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bbmt.2020.01.013","article-title":"Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching","volume":"26","author":"Oltolini","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/bmt.2014.37","article-title":"Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients","volume":"49","author":"Gudiol","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.bbmt.2018.01.021","article-title":"Single Antigen\u2013Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors","volume":"24","author":"Jorge","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"619.e1","DOI":"10.1016\/j.jtct.2021.03.022","article-title":"High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation","volume":"27","author":"Pedraza","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","article-title":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00277-016-2711-1","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: Prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2008.162","article-title":"Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT","volume":"42","author":"Ljungman","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jinf.2020.06.009","article-title":"BK virus infection in allogeneic hematopoietic cell transplantation: An update on pathogenesis, immune responses, diagnosis and treatments: BK polyoma virus infection","volume":"81","author":"Saade","year":"2020","journal-title":"J. Infect."},{"key":"ref_17","unstructured":"(2024, December 01). BMT CTN Technical Document Infectious Diseases. Available online: www.astct.org\/learn\/practice-guidelines."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/QCO.0000000000000592","article-title":"Human herpesvirus 6 in transplant recipients: An update on diagnostic and treatment strategies","volume":"32","author":"Hill","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41409-022-01577-x","article-title":"Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: A study from the Acute Leukemia Working Party of the EBMT","volume":"57","author":"Battipaglia","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3324\/haematol.2017.176107","article-title":"Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: A position statement from the acute leukemia working party of the European society for blood and marrow transplantation","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","article-title":"PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation","volume":"14","author":"Penack","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41375-020-0863-4","article-title":"Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9\/10 or 10\/10 HLA-matched unrelated donors for acute leukemia","volume":"35","author":"Lorentino","year":"2021","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/cncr.30180","article-title":"Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation","volume":"122","author":"Gaballa","year":"2016","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/bloodadvances.2017014464","article-title":"Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD","volume":"2","author":"Bejanyan","year":"2018","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","article-title":"Patterns of infection and infectious-related mortality in patients receiving post-transplant high dose cyclophosphamide as graft-versus-host-disease prophylaxis: Impact of HLA donor matching","volume":"56","author":"Irene","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"50.e1","DOI":"10.1016\/j.jtct.2021.10.008","article-title":"Bloodstream Infections and Outcomes Following Allogeneic Hematopoietic Cell Transplantation: A Single-Center Study","volume":"28","author":"Carreira","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s15010-017-1016-1","article-title":"A review of infectious complications after haploidentical hematopoietic stem cell transplantations","volume":"45","author":"Atilla","year":"2017","journal-title":"Infection"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/ciy658","article-title":"Incidence, Risk Factors, Microbiology and Outcomes of Pre-engraftment Bloodstream Infection after Haploidentical Hematopoietic Stem Cell Transplantation and Comparison With HLA-identical Sibling Transplantation","volume":"67","author":"Yan","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41409-019-0475-7","article-title":"Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: A study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC)","volume":"54","author":"Fayard","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/s41409-024-02388-y","article-title":"Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: Clinical and in vitro examination of endothelial activation","volume":"59","author":"Pedraza","year":"2024","journal-title":"Bone Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.bbmt.2019.12.217","article-title":"Incidence and Impact of Cytomegalovirus Infection in Haploidentical and Matched-Related Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis","volume":"26","author":"Goldsmith","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: A CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-023-05542-6","article-title":"Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: A real-world, observational study","volume":"103","author":"Brusosa","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1450.e1","DOI":"10.1016\/j.cmi.2023.07.026","article-title":"Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis","volume":"29","author":"Kampouri","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kampouri, E., Handley, G., and Hill, J.A. (2024). Human Herpes Virus-6 (HHV-6) Reactivation after Hematopoietic Cell Transplant and Chimeric Antigen Receptor (CAR)- T Cell Therapy: A Shifting Landscape. Viruses, 16.","DOI":"10.3390\/v16040498"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"48.e1","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2023.07.007","article-title":"Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation","volume":"29","author":"Salas","year":"2023","journal-title":"Transpl. Cell. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41409-021-01364-0","article-title":"Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation","volume":"56","author":"Mac","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jtct.2022.05.012","article-title":"A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant","volume":"28","author":"Ngo","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/tid.12365","article-title":"Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis","volume":"17","author":"Crocchiolo","year":"2015","journal-title":"Transpl. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jtct.2021.07.023","article-title":"Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation","volume":"27","author":"Khimani","year":"2021","journal-title":"Transplant. Cell. Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1109\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:00:23Z","timestamp":1760029223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071109"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071109","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}